Maria-Victoria Mateos, MD, PhD from the University Hospital of Salamaca, Spain discusses the importance of identifying frail/elderly patients using well-establish…
Browsing: Acute Lymphoblastic Leukemia
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the highlights in the field…
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about biomarkers of cardiotoxicity in…
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about cardio-oncology in multiple myeloma…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses why MSI-high cancers are more responsive to immune checkpoint…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how the STEAM trial may not change treatment paradigm…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses RAS mutation in patients with metastatic colorectal cancer at…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses planned studies to evaluate immune checkpoint inhibitors in MMR…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses PD-L1 markers in MMR deficient cancers at ASCO GI…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses mutational load of colorectal and non-colorectal cancers may benefit…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses Mismatch Repair (MMR) deficient and the use of PD-1…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses the MAVERICC Phase II study results at ASCO GI…
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how ERCC1 not a valid prognostic or predictive factor…
Alan P. Venook, MD of University of California San Francisco discusses TAS-102 versus 5-flourouracil and other more familiar agents at…
Alan P. Venook, MD of University of California San Francisco discusses TAS-102 Adverse events compared to other approved flouropyrmidines at…
Alan P. Venook, MD of University of California San Francisco discusses RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in…
Alan P. Venook, MD of University of California San Francisco discusses RECOURSE trial and if performance status impact benefit from…
Alan P. Venook, MD of University of California San Francisco discusses the primary and secondary endpoints of the RECOURSE trial…
Alan P. Venook, MD of University of California San Francisco discusses integrating TAS-102 and regorafenib into your therapeutic algorithm for…
Alan P. Venook, MD of University of California San Francisco discusses the importance of performance status prior to starting regorafenib…
Alan P. Venook, MD of University of California San Francisco discusses which EGFR inhibitor to use in second line treatment…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Michael Hallek, MD from the University of Cologne, Cologne, Germany, discusses the novel therapies being presented at the American Society…
Michael Hallek, MD from the University of Cologne, Cologne, Germany, discusses associated with long-term therapies in chronica lymphocytic leukemia (CLL).…
Michael Hallek, MD from the University of Cologne, Cologne, Germany, provides an overview of main chronic lymphocytic leukemia (CLL) studies…
Andrew Davies, MD, BSc, MRCP, PhD, from the University of Southampton, Southampton, UK provides an overview of the REMoDL-B clinical…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Daniel Catenacci, MD of The University of Chicago Medicine discusses weekly T-DM1 surprising or disappointing at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas at…
Daniel Catenacci, MD of The University of Chicago Medicine discusses the ToGA trial and how it changed the management of…
Daniel Catenacci, MD of The University of Chicago Medicine discusses post-operative adjuvant therapy for resectable patients with node positive esophageal…
Daniel Catenacci, MD of The University of Chicago Medicine discusses the NEOSCOPE trial results and management of resectable esophageal adenocarcinoma…
Daniel Catenacci, MD of The University of Chicago Medicine discusses why the NEOSCOPE trial may not be significantly and clinically…
Daniel Catenacci, MD of The University of Chicago Medicine discusses GATSBY trial results T-DM1 in previously treated gastric and GE…
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or…
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept adding anti-angiogenic agent to chemotherapy in advanced…
The Role of PD-L1 Pathway in Cancer Immune Invasion
The Importance of PD-L1 Expressions on Tumor and Immune Cells
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Peter Van Loo, PhD, from The Francis Crick Institute, London,…
Howard S Hochster, MD of Yale Medical Center discusses adverse event profile for TAS-102 at ASCO GI 2016
Howard S Hochster, MD of Yale Medical Center discusses the future of TAS-102 and regorafenib for patients with colorectal cancer…
Howard S Hochster, MD of Yale Medical Center discusses Phase III RECOURSE trial on which FDA approval for TAS-102 was…
Howard S Hochster, MD of Yale Medical Center discusses RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib at ASCO…
Howard S Hochster, MD of Yale Medical Center discusses TAS-102 and how it differ from more familiar agents, such as…
Davendra Sohal, MD of Cleveland Clinic discusses the reason microsatellite instability responds to immunotherapy in colon cancer at ASCO GI…